Pfizer Return on Tangible Equity 2010-2024 | PFE
Current and historical return on tangible equity values for Pfizer (PFE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Pfizer Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-2.60B |
$-41.71B |
8.71% |
| 2024-03-31 |
$-0.31B |
$-39.57B |
1.74% |
| 2023-12-31 |
$2.12B |
$-43.40B |
-35.51% |
| 2023-09-30 |
$10.48B |
$5.45B |
202.57% |
| 2023-06-30 |
$21.47B |
$6.32B |
281.19% |
| 2023-03-31 |
$29.05B |
$7.76B |
354.91% |
| 2022-12-31 |
$31.37B |
$1.17B |
453.96% |
| 2022-09-30 |
$29.77B |
$15.30B |
402.58% |
| 2022-06-30 |
$29.31B |
$8.51B |
811.15% |
| 2022-03-31 |
$24.97B |
$2.66B |
-10680.64% |
| 2021-12-31 |
$21.98B |
$3.11B |
-703.67% |
| 2021-09-30 |
$19.43B |
$0.17B |
-258.89% |
| 2021-06-30 |
$12.76B |
$-6.88B |
-91.88% |
| 2021-03-31 |
$10.68B |
$-8.90B |
-56.16% |
| 2020-12-31 |
$9.16B |
$-14.42B |
-38.64% |
| 2020-09-30 |
$7.73B |
$-25.33B |
-31.20% |
| 2020-06-30 |
$13.94B |
$-27.43B |
-52.60% |
| 2020-03-31 |
$15.50B |
$-27.63B |
-59.02% |
| 2019-12-31 |
$16.03B |
$-18.69B |
-60.60% |
| 2019-09-30 |
$16.22B |
$-32.27B |
-57.94% |
| 2019-06-30 |
$12.65B |
$-26.45B |
-46.45% |
| 2019-03-31 |
$11.48B |
$-28.37B |
-39.99% |
| 2018-12-31 |
$11.15B |
$-24.86B |
-37.19% |
| 2018-09-30 |
$23.82B |
$-29.26B |
-74.36% |
| 2018-06-30 |
$22.55B |
$-32.30B |
-62.82% |
| 2018-03-31 |
$21.75B |
$-33.54B |
-54.73% |
| 2017-12-31 |
$21.31B |
$-33.04B |
-49.06% |
| 2017-09-30 |
$9.81B |
$-44.69B |
-20.88% |
| 2017-06-30 |
$8.32B |
$-47.67B |
-17.51% |
| 2017-03-31 |
$7.30B |
$-48.34B |
-16.86% |
| 2016-12-31 |
$7.22B |
$-47.26B |
-19.29% |
| 2016-09-30 |
$6.27B |
$-46.92B |
-19.91% |
| 2016-06-30 |
$7.04B |
$-30.59B |
-27.51% |
| 2016-03-31 |
$7.62B |
$-24.81B |
-38.29% |
| 2015-12-31 |
$6.96B |
$-23.60B |
-43.91% |
| 2015-09-30 |
$8.36B |
$-23.39B |
-73.63% |
| 2015-06-30 |
$8.90B |
$-7.82B |
-155.92% |
| 2015-03-31 |
$9.18B |
$-8.60B |
-203.23% |
| 2014-12-31 |
$9.14B |
$-5.61B |
-304.70% |
| 2014-09-30 |
$10.48B |
$-0.79B |
-359.26% |
| 2014-06-30 |
$10.40B |
$-3.07B |
-268.97% |
| 2014-03-31 |
$21.58B |
$-2.52B |
-489.67% |
| 2013-12-31 |
$22.00B |
$-5.28B |
-436.94% |
| 2013-09-30 |
$25.75B |
$-4.60B |
-468.44% |
| 2013-06-30 |
$26.37B |
$-5.23B |
-392.72% |
| 2013-03-31 |
$15.53B |
$-5.03B |
-179.32% |
| 2012-12-31 |
$14.57B |
$-7.13B |
-132.53% |
| 2012-09-30 |
$9.69B |
$-9.46B |
-77.59% |
| 2012-06-30 |
$10.22B |
$-13.01B |
-80.20% |
| 2012-03-31 |
$9.58B |
$-14.38B |
-74.87% |
| 2011-12-31 |
$10.01B |
$-13.13B |
-80.67% |
| 2011-09-30 |
$11.46B |
$-10.48B |
-92.21% |
| 2011-06-30 |
$8.59B |
$-13.20B |
-64.11% |
| 2011-03-31 |
$8.45B |
$-12.82B |
-57.43% |
| 2010-12-31 |
$8.26B |
$-13.22B |
-52.34% |
| 2010-09-30 |
$6.13B |
$-14.35B |
-35.14% |
| 2010-06-30 |
$8.15B |
$-18.50B |
-119.98% |
| 2010-03-31 |
$7.93B |
$-17.05B |
196.24% |
| 2009-12-31 |
$8.64B |
$-19.95B |
62.52% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$159.177B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
